Evotec SE

EVT

Company Profile

  • Business description

    Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

  • Contact

    Essener Bogen 7
    22419 Hamburg
    Hamburg22419
    DEU

    T: +49 40560810

    E: [email protected]

    https://www.evotec.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    4,553

Stocks News & Analysis

stocks

ASX healthcare giant rallies despite a fall in profits

Easing investor concerns and signalling a return to growth.
stocks

Weekly earnings wrap: BHP, CSL, NAB and more

Materials, banking, healthcare and retail heavyweights reveal diverging outlooks.
stocks

Chart of the Week: Our top dividend stock picks on the ASX

Highlighting key income opportunities on the ASX.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,298.509.60-0.10%
CAC 408,451.4950.42-0.59%
DAX 4025,917.13174.20-0.67%
Dow JONES (US)53,463.05119.650.22%
FTSE 10010,693.1250.23-0.47%
HKSE25,698.49203.420.80%
NASDAQ26,331.0941.380.16%
Nikkei 22566,216.79890.371.36%
NZX 50 Index13,919.829.85-0.07%
S&P 5007,707.980.000.00%
S&P/ASX 2009,083.8018.00-0.20%
SSE Composite Index3,903.729.300.24%

Market Movers